Table 1 Clinical study patient characteristics (n = 21).

From: Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Pt

Sex

Age

Disease

Cyto genetics

Chemotherapy cycles

Pretreatment Regimen

BM Blast pre-lymphodepletion (%)

GC007F cell dose

CAR+ (%)

CRS

ICANS

CR

1

F

39

Ph+ B-ALL

T315I/V299L

5

VDLP + TKI×2, CAM×1 HyperCVAD (Part B) + TKI × 2

0.71

DL1

31.8

1

No

MRD-

2

F

14

Ph- B-ALL

Normal

3

VDLP × 1, CAM × 1 HyperCVAD (Part B) × 1

0.05

DL1

33.30

No

No

MRD-

3

F

27

Ph- B-ALL

Normal

4

CVDLP × 2 HyperCVAD (Part B) × 2

87.87

DL1

32

3

No

MRD-

4

F

27

Ph+ B-ALL

CALR, T315I

5

VDLP + TKI×3 CAM + TKI×1 HyperCVAD (Part B) + TKI × 1

85.47

DL2

40.1

2

No

MRD+

5

M

25

Ph+ B-ALL

BCR/ABL

3

CVDLP + TKI × 2 HyperCVAD (Part B) + TKI × 1 Allogeneic transplant

47.86

DL2

15.1

3

No

MRD-

6

F

21

Ph- B-ALL

Normal

4

VDLP × 2 HyperCVAD (Part B) × 2

0.05

DL2

19.1

3

No

MRD-

7

M

15

Ph+ B-ALL

BCR/ABL

5

VDLP + TKI × 2 CAM + TKI × 1 HyperCVAD (Part B) + TKI × 2

0.45

DL2

46.1

3

No

MRD-

8

M

15

Ph- B-ALL

Normal

3

VDLP × 1 HyperCVAD (Part B) × 2

7.27

DL2

33.7

3

3

MRD-

9

M

24

Ph- B-ALL

TEL/AML

5

CVDLP × 3 HyperCVAD (Part B) × 2

94.01

DL2

42

2

3

MRD-

10

F

61

Ph- B-ALL

IKZF1,SH2B3

5

VDLP + TKI × 3 HyperCVAD (Part B) + TKI × 2

0.01

DL2

26.1

2

No

MRD-

11

M

47

Ph- B-ALL

Normal

2

CVDLP × 1, CAM × 1

59.74

DL2

42.2

2

No

MRD-

12

F

41

Ph- B-ALL

Normal

2

VDLP × 2

57.14

DL2

39.5

3

No

MRD-

13

M

17

Ph- B-ALL

Normal

7

VDLP × 4, CAM × 2 HyperCVAD (Part B) × 1

17.86

DL3

46.9

3

2

MRD-

14

F

18

Ph- B-ALL

E2A-PBX1

5

VDLP × 2, CAM × 1 HyperCVAD (Part B) × 2 Allogeneic transplant

1.77

DL3

50.9

3

1

MRD-

15

M

32

Ph- B-ALL

Normal

5

CVDLP × 2, CAM × 1 HyperCVAD (Part B) × 2

69

DL3

46

2

No

MRD-

16

F

14

Ph- B-ALL

WTI

5

CVILP × 2, CAM × 1 HyperCVAD (Part B) × 2

1.67

DL3

40.1

3

3

MRD-

17

F

44

Ph- B-ALL

Normal

5

CVILP × 2, CAM × 1 HyperCVAD (Part B) × 2 Allogeneic transplant

38.5

DL3

60.4

2

No

MRD-

18

M

47

Ph- B-ALL

Normal

9

CVDLP × 2, CAM × 1 HyperCVAD (Part B) × 2, et al.

85.29

DL3

39.4

3

No

MRD-

19

F

32

Ph- ALL

MLL-AF4

2

VDLP × 1 HyperCVAD (Part B) × 1

87.31

DL2

26.8

2

2

NE

20

M

44

Ph- ALL

Normal

5

CVDLP × 2, CAM × 1 HyperCVAD (Part B) × 2

62

DL2

21.3

4

No

NE

21

M

45

Ph- ALL

Normal

25

CVDLP × 3, CAM × 1, HyperCVAD (Part B) × 2, et al.

92.3

DL3

43.3

3

No

NE

  1. Pt Patient, CAR-T cell chimeric antigen receptor T cell, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, CR complete remission, MRD minimum residual disease, Ph+-B-ALL Philadelphia chromosome positive acute lymphoblastic leukemia, Ph--B-ALL Philadelphia chromosome negative acute lymphoblastic leukemia, BM bone marrow, VDLP vincristine, daunorubicin, L-asparaginase and prednisone, TKI Tyrosine Kinase Inhibitor, HyperCVAD (Part B): dexamethasone, methotrexate and cytarabine, CAM cyclophosphamide, cytarabine, 6-mercaptopurine, CVDLP cyclophosphamide, vincristine, daunorubicin, L-asparaginase and prednisone, CVILP cyclophosphamide, vincristine, idarubicin, L-asparaginase and prednisone, NE Not evaluable.
Back to article page